Slaughter and May, Hong Kong, advised BVCF Management, as a Series B investor, in relation to the US$325 million series B financing in BioNTech SE

Slaughter and May, Hong Kong, advised BVCF Management, as a Series B investor, in relation to the US$325 million series B financing in BioNTech SE, a Germany-based clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases. BVCF was founded in 2005 as China’s first US dollar fund that invests in the life sciences, industrial, medical devices and health care sectors. The financing was one of the largest single private funding rounds for a biotechnology company in Europe. The proceeds of the financing will support the continued advancement of BioNTech’s therapeutics pipeline and manufacturing infrastructure.